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Background/Aims: Compact lipiodol uptake without 
enhancement on multiphasic helical computed tomog-
raphy (CT) has been suggested as a radiologic re-
sponse criterion in hepatocellular carcinoma (HCC) 
patients treated with transarterial chemoembolization 
(TACE) and subsequent partial hepatectomy. However, 
its usefulness has not been fully investigated in the 
explanted liver. Methods: Between 1998 and 2007, 
81 patients with HCC underwent 1-9 sessions of 
TACE followed by liver transplantation (LT). Thirty-nine 
tumors in 29 patients showed a radiologic response 
on CT performed prior to LT. The radiologic response 
criteria and the duration of the response were eval-
uated to predict total necrosis in the explanted liver. 
Results: Among the 39 tumors, 34 nodules (87.2%) 
exhibited total pathological necrosis. While 13 out of 
16 tumors (81.3%) with a radiologic response for 6 
months or less were completely necrotic, 21 out of 23 
tumors (91.3%) with a radiologic response of longer 
than 6 months showed total necrosis. Conclusions: 
Our results suggested that the radiologic response cri-
teria based on serial CT images might be useful for 
predicting total necrosis of TACE-pretreated HCC in 
LT.  (Gut and Liver 2009;3:285-291)
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INTRODUCTION
    Hepatocellular carcinoma (HCC) is a major global 
health problem responsible for approximately one million 
deaths annually.
1-3 The recommended curative treatments 
for HCC include liver transplantation (LT), surgical re-
section, radiofrequency ablation, and percutaneous etha-
nol injection.
4 LT is an ideal treatment option, as it si-
multaneously cures HCC and replaces the premalignant 
cirrhotic liver.
5-8 Furthermore, LT is the only curative 
therapy for HCC when neither surgical resection nor per-
cutaneous ablation is feasible. Considering the limited or-
gan supply, high cost, and considerable risk associated 
with LT, only those patients with a high probability of 
survival benefit should be selected to receive the 
procedure. Milan criteria (solitary HCC＜5 cm or no more 
than 3 nodules smaller than 3 cm) have been accepted in 
conventional clinical practice as selection criteria for LT. 
The 5-year survival rate after LT exceeds 70% in patents 
within this criteria.
4,9 Several groups have reported a 
5-year survival rate of approximately 50% after LT in pa-
tients with HCC when expanded criteria based on the 
pathology of the explanted liver were used.
10,11
  Transarterial chemoembolization (TACE) is the most 
frequently applied palliative treatment modality for HCC 
and is an important bridging therapy before LT,
12,13 par-
ticularly in areas where the transplant waiting list time 
exceeds 6 months including our country.
4 TACE has been 
used prior to LT in an attempt to delay tumor growth or 
to achieve down-staging of HCC. An evaluation of the pa-
tient’s response to TACE is essential in order to predict 
the outcome after LT. Conventional World Health Organi-
zation (WHO) criteria used for the estimation of systemic 
chemotherapy effects on cancer is not applicable to assess 286   Gut and Liver, Vol. 3, No. 4, December 2009
the therapeutic efficacy of TACE.
14 Therefore, other imag-
ing criteria have been suggested to estimate the possi-
bility of residual or recurrent tumor after TACE.
15-17
  Compact lipiodol uptake without enhancement on mul-
tiphasic helical computed tomography (CT) has been sug-
gested as radiologic response criteria for HCC treated 
with TACE.
15,18-20 A recent study performed at our in-
stitution showed that, when depicting viable tumors in 
HCC patients who were treated with TACE followed by 
partial hepatectomy, a review of the multiphasic helical 
CT together with the previous serial CT images could 
help to reach a correct diagnosis for those lesions that 
were incorrectly diagnosed using the reviews of the last 
CT alone.
21 However, most of the previous studies eval-
uated HCC patients who underwent partial hepatectomy 
after TACE and it has not been known whether radiologic 
response criteria using multhphasic helical CT could be 
used to predict complete necrosis in the explanted 
liver.
16,17,22 Furthermore, the reasonable or sufficient dura-
tion of radiologic response to predict complete necrosis 
has not been fully investigated.
  In this study, we reviewed the serial multiphasic helical 
CT images and pathologic specimens of explanted liver 
from patients with HCC treated with TACE followed by 
LT to evaluate the effectiveness of radiologic response cri-
teria using multiphasic helical in predicting complete ne-
crosis in the explanted liver.
MATERIALS AND METHODS
1. Patient selection
  From January 1998 to December 2007, 81 patients with 
hepatocellular carcinoma underwent TACE followed by LT 
at our hospital. HCC was diagnosed based on pathology 
or clinical diagnostic criteria for HCC suggested by the 
Korean Liver Cancer Study Group (KLCSG) and the 
N a t i o n a l  C a n c e r  C e n t e r  ( N C C )  i n  K o r e a .  A c c o r d i n g  t o  
this diagnostic criteria, in a patient positive for one or 
more risk factors (Hepatitis B or C virus positive, or cir-
rhosis), HCC can be diagnosed if one or more imaging 
techniques indicate HCC and serum alpha-fetoprotein 
(AFP) level≥400 ng/mL, or two or more imaging techni-
ques indicate HCC when AFP level does not reach the 
suggested value. Spiral CT scan, gadolinium/SPIO-enhan-
ced dynamic MRI, or hepatic artery angiography can be 
used for this purpose.
23
  Multiphasic helical liver CT images were serially taken 
every 3-4 months between the TACE and LT procedures. 
The liver CT images were retrospectively reviewed by a 
single expert radiologist who was blind to the pathologic 
findings of the explanted liver. Tumors with compact lip-
iodol uptake and without any contrast-enhanced areas on 
a multiphasic helical CT scan were defined as having a ra-
diologic response to TACE. The following lesions were 
regarded as viable areas on the CT images: (i) a hyper-
attenuating or isoattenuating lesion seen during the hep-
atic arterial phase seen as a hypoattenuating lesion during 
the portal venous phase of the delayed phase, (ii) an area 
of mixed attenuation seen on the hepatic arterial phase 
images, which shows a hypoattenuating portion on either 
the portal venous phase or the delayed phase, and (iii) a 
nodule that was seen as isoattenuating on the hepatic ar-
terial phase, the portal venous phase, or the delayed 
phase images, but seen as hypoattenuating on the un-
enhanced images.
15
  Twenty-nine patients with a single or multiple tumors 
fulfilling these radiologic response criteria on multiphasic 
helical CT taken just prior to liver transplantation were 
recruited. The response duration was defined as the time 
interval between the first CT showing a radiologic response 
and the last CT keeping the initial radiologic response.
2. Multphasic helical CT
    CT was performed with a helical scanner (HiSpeed 
Advantage; GE Medical Systems, Milwaukee, WI, USA) 
with 5 mm section collimation, 2.5 mm interval, and 
39.37 mm/sec table speed during a 25-30 second single 
breath-hold helical acquisition. After an IV injection of 
120 mL nonionic iodinated contrast material (Iopamiro 
300, Bracco, Milano, Italy; Ultravist 300, Schering, Berlin, 
Germany) at a speed of 3 mL/sec, the hepatic arterial 
phase, the portal venous phase, and the delayed phase 




    Initially, selective angiography was performed in all 
patients. After identifying the tumor-feeding artery, trans-
arterial chemoembolization was performed with a mixture 
of iodized oil (Lipiodol; Guerbet, Aulnay-sous-Bois, 
France) and doxorubicin hydrochloride (Adriamycin; 
Kyowa Hakko Kogyo, Tokyo, Japan) in all patients. For 
each 1-cm diameter of the tumor, 3 mg of doxorubicin 
hydrochloride and 1 cc of iodized oil were used. The in-
jection was continued until stasis was identified in the 
feeding artery.
21
4. Pathologic analysis and evaluation of predictive 
factors for complete necrosis
  The explanted specimens of the tumors were reviewed 
by a single experienced liver pathologist. The pathologic 
specimens were sectioned at 5-mm thickness and the ex-Kim SJ, et al: Complete Necrosis of HCC Treated with TACE   287
Table 1. Baseline Characteristics of 29 Patients and 39 
Tumors
Characteristics N




AFP (ng/mL*)  11.3 (1-3259)
HBe Ag (+/-)  9/20
HBV DNA level (pg/mL*)  4.4 (0.6-1078)
Anti-viral treatment (+/-) 10/19
Sessions of TACE    3 (1-9)
Time interval between last TACE  3.9 (1-28)
 and LT (months*)
LT (cadaveric/living donor)  5/24
No. of tumors with radiologic 23/4/1/0/1
 response (1/2/3/4/5)
Size of tumor (cm*)  1.5 (0.5-4.8)
LC, liver cirrhosis; AFP, alpha-fetoprotein; TACE, transarterial 
chemoembolization; LT, liver transplantation.
*Data are shown as median (range).

















1 4 8 M     1 3 1 S 4 4 . 3 2 0
2 56 M 1,600 1 1.5 S2 1.6 95
3 55 M  12.3 6 0.9 S7 11.6 99
46 8 F   7 . 8 2 2 S 6 6 . 8 9 9
5 54 M   3.2 2 1.2 S6 2.4 95
tent of tumor necrosis was estimated as a proportion of 
the area showing complete necrosis over the total tumor 
area. The percentage of tumor necrosis was determined 
after evaluating all of the sections.
21
  We evaluated the characteristics of patients and tumors 
and investigated any possible predictive factors for patho-
logic complete necrosis on explanted liver.
5. Statistical analysis
  The Chi-square test and Student’s t-test were used for 
data analysis. All p values were two-tailed and p values 
less than 0.05 were considered statistically significant. 
Data analyses were performed using statistics package SAS 
Enterprise Guide 3.0 (SAS Institute Inc., Cary, NC, USA).
RESULTS
1. Patient and tumor characteristics
  A total of 39 tumors from 29 patients showed compact 
lipiodol uptake on multiphasic helical CT taken before 
LT. These patients included 25 males and 4 females, with 
a median age of 55 (range, 42 to 68). All of the patients 
had hepatitis B virus (HBV) infection and 28 patients 
(96.6%) showed cirrhosis on pathologic examination of 
explanted liver. One to 9 sessions (median 3) of TACE 
were performed before LT. The last TACE session was 
performed 1 to 28 months (median 3.9) prior to LT. Five 
patients received cadaveric liver and 24 patients received 
a liver from a living donor. The number of tumors show-
ing radiologic response was as follows: one in 23 patients 
(79.3%), two in 4 patients (13.9%), three in 1 patient 
(3.4%), and five in 1 patient (3.4%). The tumor size 
based on the pathology of explanted liver was 0.5 cm to 
4.8 cm (median 1.5) (Table 1).
2. Pathologic complete necrosis and predictive fac-
tors
  We examined the pathology of 39 tumors with a radio-
logic response in the explanted liver. While 34 nodules 
(87.2%) showed total necrosis, 5 nodules (12.8%) still 
showed a viable portion on the explanted specimen. The 
detailed characteristics of 5 cases of HCC showing in-
complete necrosis independent of radiologic response are 
summarized in Table 2. A representative case of HCC 
showing complete necrosis in the explanted liver and one 
showing incomplete necrosis are shown in Figs. 1 and 2, 
respectively.
  We investigated any possible factors that could predict 
complete necrosis in the tumor nodules showing a radio-
logic response. Tumors with complete necrosis and those 
with incomplete necrosis showed no significant differ-
ences in the source patients’ age, sex, serum AFP level, 
HBeAg positivity, HBV DNA level, or presence of anti-
viral treatment; the tumors also did not differ sig-
nificantly in size (Table 3).
  The duration of radiologic response in nodules with 
complete necrosis tended to be higher than those with in-
complete necrosis (13.6±13.8 vs 5.2±4.0 months), al-
though the difference was not statistically significant 288   Gut and Liver, Vol. 3, No. 4, December 2009
Fig. 1. Two hepatocellular carcinoma (HCC) nodules with a radiologic response of 39.1 months showing complete necrosis in the
explanted liver. (A-C) Computed tomography (CT) showing HCC nodules of 2.5 cm and 2.6 cm with complete lipiodol uptake 
without enhancement (A, precontrast imaging; B, arterial phase; C, delayed phase). (D) Total tumor necrosis was observed in the
explanted liver (H&E stain, ×50).
(p=0.20). While 13 (81.3%) of 16 tumors with a radio-
logic response for 6 months or less were completely ne-
crotic, 21 (91.3%) of 23 tumors with a radiologic re-
sponse longer than 6 months showed total necrosis. All 
13 tumors (100%) with a radiologic response over 12 
months were completely necrotic on the pathologic speci-
men (Table 4).
DISCUSSION
  TACE is one of the common bridging treatments prior 
t o  L T  i n  g e n e r a l  c l i n i c a l  p r a c t i c e  f o r  H C C .  I n  H C C  p a -
tients who underwent TACE and were expecting LT, ac-
curate staging based on reliable response criteria is in-
valuable to predict the outcome after LT and to de-
termine whether he or she will remain on the waiting list 
or not. Since the extent of necrosis after TACE in HCC 
patients is poorly correlated with the reduction in tumor 
diameter, the WHO criteria or Response Evaluation 
Criteria in Solid Tumors (RECIST) conventionally used 
for the evaluation of the response to systemic chemo-
therapy cannot be applied for these patients.
17,21,24,25
  Hence, several studies have suggested other radiologic 
response criteria based on CT imaging to assess the effect 
of TACE on HCC. A study suggested that CT could be a 
suitable tool for the evaluation of the efficacy of TACE in 
patients receiving the treatment followed by partial hep-
atectomy based on the assumption that the portion of tu-
mor that retains iodized oil was necrotic. The radiologic 
tumor necrosis rate calculated on this assumption showed 
good correlation with the pathologic necrosis rate.
17 In 
addition, volumetric and morphologic CT criteria were re-Kim SJ, et al: Complete Necrosis of HCC Treated with TACE   289
Fig. 2. A hepatocellular carcinoma nodule with a radiologic response of 2.4 months showing incomplete necrosis in the explanted 
liver. (A-C) CT showing a 1.2-cm hepatocellular carcinoma (HCC) nodule with complete lipiodol uptake without enhancement (A,
precontrast imaging; B, arterial phase; C, delayed phase). (D) The tumor shows a 95% necrotic portion and a 5% viable portion in
the explanted liver (H&E stain, ×50).
Table 3. Comparison of Tumors with Complete Necrosis and Those with Incomplete Necrosis
Characteristics Complete necrosis (n=34) Incomplete necrosis (n=5) p-value
Age (years*) 53.5 (23) 55 (20) 0.30
Sex (male/female) 31/3 3/2 0.11
LC (+/-) 33/1 5/0 1.00
AFP (ng/mL*)   11.8 (3258) 7.8 (1599) 0.98
HBe Ag (+/-) 11/23 1/4 1.00
HBV DNA level (pg/mL*)  1.7 (1078.1) 0.6 (0) 0.68
Anti-viral treatment (+/-) 11/23 2/3 1.00
Sessions of TACE*    3 (8)   2 (5) 0.78
Time interval between last TACE and LT (months*)  3.6 (27.4) 4.6 (9.8) 0.72
LT (cadaveric/living donor)  6/28 0/5 0.5
Size of tumor (cm*)  1.6 (4.3) 1.2 (1.1) 0.34
LC, liver cirrhosis; AFP, alpha-fetoprotein; TACE, transarterial chemoembolization; LT, liver transplantation.
*Data are shown as median (range).
ported to be useful for the assessment of prognosis and 
therapeutic success.
22 New radiologic response criteria 
that included the extent of tumor necrosis was recently 
suggested by the European Association for the Study of 
the Liver (EASL).
26 The recent report from our center 
demonstrated that a review of serial multiphasic helical 290   Gut and Liver, Vol. 3, No. 4, December 2009
Table 4. Complete Necrosis According to the Duration of 







＜6 month 13 (81.3%) 3 (18.8%)
≥6 month 21 (91.3%) 2 (8.7%)
≥12 month 13 (100%) 0 (0.0%)
CT images of viable tumor in HCC patients treated with 
TACE could help to render a correct diagnosis for those 
lesions that were incorrectly diagnosed depending solely 
on the review of the latest CT.
21 Compact lipiodol uptake 
without enhancement on multiphasic helical CT has been 
suggested in previous studies as response criteria to pre-
dict complete necrosis for HCC patients receiving partial 
hepatectomy after TACE. However, its usefulness has not 
been fully investigated for the explanted liver. Further-
more, the adequate duration of radiologic response to en-
sure complete pathologic necrosis was not known.
16,17,22
  To our best knowledge, our study is the first to show 
that complete lipiodol uptake without enhancement on 
serial multiphasic helical CT could be useful in predicting 
complete pathologic necrosis in the explanted liver for 
HCC patients treated with TACE followed by LT. In our 
study, a total of 39 tumors in 29 patients who received 1 
to 9 sessions of TACE before LT showed compact lipiodol 
uptake without enhancement on multiphasic helical CT. 
Thirty-five tumors (87.2%) showed complete necrosis in 
the explanted specimen. Although the difference was not 
statistically significant, complete necrosis tended to be 
higher in those with longer radiologic response (81.3% in 
≤6 months, 91.3% in ＞6 months, 100% in ＞12 
months).
  Our study has a few weak points. Inclusion in this 
study was done on tumor basis, not on patient basis. Any 
nodules showing radiologic response were included and 
evaluated, even though the corresponding patient has an-
other nodule without radiologic response. Newly devel-
oped HCC nodule in patients with existing tumor show-
i n g  r a d i o l o g i c  r e s p o n s e  c o u l d  l e a d  t o  s o m e  b i a s  o n  d a t a ; 
i.e., high serum AFP or additional sessions of TACE. 
However, if the patients with nodules without radiologic 
r e s p o n s e  w e r e  e x c l u d e d  i n  t h i s  s t u d y ,  i t  w o u l d  b e  v e r y  
difficult to get sufficient number of patients for any use-
ful data. In practice, patients with no viable HCC may re-
quire LT unless they show severe decompensation. Hence, 
we included the subjects on tumor basis. In addition, this 
study shares a limitation with others performed in single 
institution. Comparing the characteristics of tumors with 
complete necrosis to those with incomplete necrosis in 
explanted liver specimens, the duration of radiologic re-
sponse in the complete necrosis group tended to be lon-
ger than that in the incomplete necrosis group (13.6± 
13.8 vs 5.2±3 months); however, the difference was not 
statistically significant since the incomplete necrosis group 
was too small.
  Nevertheless, our study has some strong points. In this 
single center study including patients within the last 10 
years, TACE was performed according to a recent stand-
ardized method and multiphasic helical CT was also done 
with up-to-date equipment and a standard protocol, to 
avoid the confounding effects of diverse treatments and 
imaging. In addition, CT findings were evaluated by a sin-
gle expert radiologist not informed of the pathologic find-
ings, while the pathologic specimens were reviewed by a 
single experienced liver pathologist. Above all, our study 
is the first to show that radiologic response, possibly a 
durable one, is useful to predict complete necrosis in the 
explanted liver from HCC patients after TACE.
    Our results suggested that compact lipiodol uptake 
without enhancement on multiphasic helical CT could be 
useful criteria to predict total necrosis of HCC nodules in 
explanted liver treated with TACE prior to LT. Further 
studies are warranted to clarify the role of durable radio-
logic response on serial CT as a predictor for complete 
necrosis.
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